Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of Aβ Fibrillation
Source abstract
Abstract
Anti-Aβ therapy has dominated clinical trials for the prevention and treatment of Alzheimer’s disease (AD). However, suppressing Aβ aggregation and disintegrating mature fibrils simultaneously remains a great challenge. In this work, we developed a new strategy using a charged tubular supramolecule (CTS) with pillar[5]arene as the backbone and modifying amino and carboxyl groups at the tubular terminals (noted as CTS-A, CTS-A/C, and CTS-C, respectively) to suppress Aβ fibrillation for the first time. According to the spectroscopic and microscopic characterizations, Aβ40 fibrillation can be efficiently suppressed by CTS-A in a very low inhibitor:peptide (I:P) molar ratio (1:10). A greatly alleviated cytotoxic effect of Aβ peptides after the inhibition or disaggregation process is further disclosed. The well-organized supramolecular structure drives multivalent interaction and gains enhanced efficiency on amyloid fibrillar modulation. These results open a new path for the design of supramolecules in the application of AD treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · Alzheimer's disease research and treatments · Supramolecular Chemistry and Complexes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry, Zhengzhou University, Zhengzhou, 450001, China
State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, College of Chemistry, Nankai University, Tianjin 300071, China
Department of Chemistry, Fudan University, Shanghai 200433, China
School of Medicine, Nankai University, Tianjin 300071, China
Funding
National Natural Science Foundation of China
References (39)
Show source-provided references
1. 10.1038/nrd.2016.28110.1038/nrd.2016.281 ↗
2. 10.1126/science.aay518810.1126/science.aay5188 ↗
3. 10.1038/nrm381010.1038/nrm3810 ↗
4. 10.1038/nrd350510.1038/nrd3505 ↗
5. 10.1126/science.107299410.1126/science.1072994 ↗
6. 10.3389/fnins.2018.0002510.3389/fnins.2018.00025 ↗
7. 10.1021/cr300009x10.1021/cr300009x ↗
8. 10.1039/b807980n10.1039/b807980n ↗
9. 10.1038/nsmb.179910.1038/nsmb.1799 ↗
10. 10.1002/anie.20200590210.1002/anie.202005902 ↗
11. 10.1021/ar200341810.1021/ar2003418 ↗
12. 10.1021/acs.chemrev.5b0076510.1021/acs.chemrev.5b00765 ↗
13. 10.1002/cjoc.20190040810.1002/cjoc.201900408 ↗
14. 10.1039/C8CS00037A10.1039/C8CS00037A ↗
15. 10.1002/anie.20180588410.1002/anie.201805884 ↗
16. 10.1002/anie.20201397510.1002/anie.202013975 ↗
17. 10.1002/adfm.20200992410.1002/adfm.202009924 ↗
18. 10.1016/j.matt.2019.08.02110.1016/j.matt.2019.08.021 ↗
19. 10.1002/anie.20201015010.1002/anie.202010150 ↗
20. 10.1039/C9CC03165K10.1039/C9CC03165K ↗
21. 10.1021/acsmacrolett.0c0071410.1021/acsmacrolett.0c00714 ↗
22. 10.1021/jacs.0c0875110.1021/jacs.0c08751 ↗
23. 10.1039/C8CC08085B10.1039/C8CC08085B ↗
24. 10.1039/D0TC04343E10.1039/D0TC04343E ↗
25. 10.1021/jacs.1c0600010.1021/jacs.1c06000 ↗
26. 10.1002/anie.20181379710.1002/anie.201813797 ↗
27. 10.1021/jacs.0c0748210.1021/jacs.0c07482 ↗
28. 10.1021/ja405014r10.1021/ja405014r ↗
29. 10.1039/C7CC08365C10.1039/C7CC08365C ↗
30. 10.1021/jacs.0c0060110.1021/jacs.0c00601 ↗
31. 10.1021/acsnano.0c0755510.1021/acsnano.0c07555 ↗
32. 10.1002/anie.20100782410.1002/anie.201007824 ↗
33. 10.1126/science.107299410.1126/science.1072994 ↗
34. 10.1021/ar800047510.1021/ar8000475 ↗
35. 10.1159/00048032010.1159/000480320 ↗
36. 10.31635/ccschem.020.20200056110.31635/ccschem.020.202000561 ↗
37. 10.1016/S0301-0082(00)00015-010.1016/S0301-0082(00)00015-0 ↗
38. 10.1111/j.1471-4159.2005.03217.x10.1111/j.1471-4159.2005.03217.x ↗
39. Culpan D. · Int. J. Mol. Epidemiol. Genet. · 2011 · 2 · 409